Clinical Trials
Open
Accrual
0%
SWOG Clinical Trial Number
S1900C
A PHASE II STUDY OF TALAZOPARIB PLUS AVELUMAB IN PATIENTS WITH STAGE IV OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER BEARING PATHOGENIC STK11 GENOMIC ALTERATIONS (LUNG-MAP SUB-STUDY)
Status Notes
S1900C will open to accrual January 16, 2020, effective 2:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
Lung Cancer
Activated
01-16-2020
Open
Phase
III
Accrual
0%
SWOG Clinical Trial Number
S1827
A Randomized Phase III Trial of MRI Surveillance with or without Prophylactic Cranial Irradiation in Small-Cell Lung Cancer
Status Notes
This study is open to accrual effective January 10, 2020 at 2:00 p.m. Pacific.
Research Committee(s)
Lung Cancer
Activated
01-10-2020
ClinicalTrials.gov Registry Number
04155034
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1922
Randomized Phase II Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma
Status Notes
The study referenced above is open for participation effective Monday, December 16, 2019 at 2:00 p.m. Eastern.
Research Committee(s)
Gastrointestinal Cancer
Activated
12-16-2019
Open
Phase
II
Accrual
0%
SWOG Clinical Trial Number
S1820
A Randomized Trial of the Altering Intake, Managing Symptoms Intervention for Bowel Dysfunction in Rectal Cancer Survivors Compared to a Healthy Living Education Control: A Feasibility and Preliminary Efficacy Study (AIMS-RC)
Research Committee(s)
Palliative and End of Life Care Committee
Activated
12-09-2019
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA4181
A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
Status Notes
Activation - Effective 10/3/19
Research Committee(s)
Lymphoma
Activated
10-03-2019
Open
SWOG Clinical Trial Number
CTSU/A071701
GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES
Status Notes
Step 0 & Step 1 Activation Effective 8/15/19; SWOG Activation Effective 9/1/19
Research Committee(s)
Brain Cancer
Activated
09-01-2019
ClinicalTrials.gov Registry Number
NCT03994796